{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/PAR.AU/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"PAR.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PAR.AU\",,,,,undefined,":{"symbol":"PAR.AU","market":"AU","secType":"STK","nameCN":"PARADIGM BIOPHARMACEUTICALS","latestPrice":0.255,"timestamp":1774588320000,"preClose":0.255,"halted":0,"volume":681259,"delay":0,"changeRate":0,"nameEN":"PARADIGM BIOPHARMACEUTICALS","floatShares":353065639,"shares":444908135,"eps":-0.10495,"marketStatus":"休市中","change":0,"latestTime":"03-27 16:12:00 AEDT","open":0.25,"high":0.255,"low":0.25,"amount":172036,"amplitude":0.019608,"askPrice":0.255,"askSize":17213,"bidPrice":0.25,"bidSize":1751275,"shortable":3,"etf":0,"ttmEps":-0.10495,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1774825200000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.255,"openAndCloseTimeList":[[1774566000000,1774587600000]],"volumeRatio":0.8426004761450335,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"PAR.AU","preClose":0.255,"auctionPrice":0.255,"auctionVolume":16190,"auction":3,"marketStatus":"盘后竞价","timestamp":1774588203507}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PAR.AU\",,,,,undefined,":{"symbol":"PAR.AU","floatShares":353065639,"roa":"-82.94%","roe":"-180.22%","lyrEps":-0.059684,"volumeRatio":0.8426004761450335,"shares":444908135,"dividePrice":0,"high":0.255,"amplitude":0.019608,"preClose":0.255,"low":0.25,"week52Low":0.24,"pbRate":"18.92","psRate":"13426.22","week52High":0.48,"institutionHeld":0,"latestPrice":0.255,"committee":0.980534,"eps":-0.10495,"divideRate":0,"volume":681259,"delay":0,"ttmEps":-0.10495,"open":0.25,"prevYearClose":0.34,"prevWeekClose":0.27,"prevMonthClose":0.26,"prevQuarterClose":0.34,"fiveDayClose":0.27,"twentyDayClose":0.26,"sixtyDayClose":0.34,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PAR.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2025-02-06","symbol":"PAR.AU","defaultRemindTime":1738796400000,"type":"split","dateTimestamp":1738760400000,"forFactor":4,"toFactor":5,"ratio":0.8},{"market":"AU","date":"2022-08-17","symbol":"PAR.AU","defaultRemindTime":1660694400000,"type":"split","dateTimestamp":1660658400000,"forFactor":992772,"toFactor":1000000,"ratio":0.992772}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PAR.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PAR.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1140711318","title":"Paradigm Biopharmaceuticals Ltd簽署口服PPS與Cox-2抑制劑組合的約束性獸藥許可與供應協議","url":"https://stock-news.laohu8.com/highlight/detail?id=1140711318","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140711318?lang=zh_tw&edition=fundamental","pubTime":"2026-02-09 06:09","pubTimestamp":1770588550,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals Ltd（PAR.AU）已正式签署一项具有约束力的兽药许可与供应协议，该协议涉及口服PPS与Cox-2抑制剂的组合疗法。这一重要合作标志着公司在兽药领域迈出关键一步，为动物医疗市场带来创新治疗方案。协议的签署不仅强化了Paradigm在生物制药行业的战略布局，也为其产品管线的多元化发展注入新动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","PAR.AU","BK7508"],"gpt_icon":0},{"id":"1127723459","title":"PARADIGM BIOPHARMACEUTICALS有望從Avet獲得高達100萬美元的開發里程碑款項","url":"https://stock-news.laohu8.com/highlight/detail?id=1127723459","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127723459?lang=zh_tw&edition=fundamental","pubTime":"2026-02-09 06:09","pubTimestamp":1770588550,"startTime":"0","endTime":"0","summary":"PARADIGM BIOPHARMACEUTICALS宣布，其有资格从合作方Avet处获得最高达100万美元的开发里程碑付款。这笔款项的支付将与特定研发进展目标的达成直接挂钩。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","PAR.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":2,"code":"91000000","status":"200"}]}}